港股異動 | 國內植髮第一股雍禾醫療(02279.HK)首日上市漲超5%
格隆匯12月13日丨雍禾醫療(2279.HK)首日上市盤中一度漲至9%,現報16.66港元,漲5.44%,總市值86.6億港元。公司此次上市擬發行9442.4萬股,另有15%超額配股權。按2020年相關所服務產生的總收入計,雍禾醫療是中國植髮醫療服務及醫療養固服務市場規模最大的企業,分別佔有10.5%及4.3%的市場份額,在中國排名均為第一。此外,公司一直在積極推動在業務中採用數據運用與分析、智能服務和在線服務等新技術。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.